Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States.

Anju Parthan M Royston A Thanataveerat E L East C S Parzynski Thomas H Brannagan

Published in: Muscle & nerve (2023)

The burden of crises/exacerbations was substantially higher and healthcare costs were considerably greater in patients with MG treated with chronic IVIg or multiple NSISTs than in patients not receiving these treatments.

Keyphrases

healthcare
myasthenia gravis
newly diagnosed
end stage renal disease
ejection fraction
chronic obstructive pulmonary disease
prognostic factors
risk factors
patient reported outcomes
patient reported
drug induced